Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | ERBB3 |
| Variant | over exp |
| Impact List | none |
| Protein Effect | no effect |
| Gene Variant Descriptions | ERBB3 (HER3) over exp indicates an over expression of the Erbb3 (Her3) protein. However, the mechanism causing the over expression is unspecified. |
| Associated Drug Resistance | |
| Category Variants Paths |
ERBB3 over exp |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05057013 | Phase Ib/II | HMBD-001 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | Active, not recruiting | GBR | 0 |
| NCT04965766 | Phase II | Patritumab deruxtecan | Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer (ICARUS BREAST) | Recruiting | FRA | 0 |